IMPROVE SLEEP.

ONE BREATH AT A TIME®

IMPROVE LIFE.

ONE DAY AT A TIME

IMPROVE SLEEP.

ONE BREATH AT A TIME®

IMPROVE LIFE.

ONE DAY AT A TIME

central sleep apnea

Central Sleep Apnea (CSA) is a serious condition that results in shallow or disrupted breathing during sleep. Learn more about the causes, symptoms, and treatment options for CSA.

Central Sleep Apnea (CSA) is a serious condition that results in shallow or disrupted breathing during sleep. Learn more about the causes, symptoms, and treatment options for CSA.

remede-system-logo

The remedē® System is an implantable, non-mask therapy designed for adult patients with moderate to severe central sleep apnea.

WATCH A VIDEO

explaining central sleep apnea and the remedē System

HEAR FROM OTHERS

Interested in seeing what others have to say about remedē? Follow the link to watch remedē patient stories.

GETTING remedē

Understand the process of getting remedē and find a doctor near you who can help determine if you are a candidate.

doctor

clinicians

Learn about remedē, including study
results, peer-reviewed publications, and
patient identification.

Learn about remedē, including study results, peer-reviewed publications, and patient identification.

Founded in 2006 and headquartered in Minnesota, Respicardia is a leader in innovative technologies that address the unmet needs of people with Central Sleep Apnea (CSA). CSA results from the brain’s inability to send appropriate signals to the respiratory muscles to stimulate breathing during sleep. CSA is a serious breathing disorder that disrupts the normal breathing pattern and negatively affects quality of life and overall health.1

The remedē® System, which received U.S. Food and Drug Administration (FDA) approval in October 2017, is a breakthrough implantable system that treats the harmful effects of CSA by restoring a more normal breathing pattern during sleep.2

  1. Costanzo MR, Khayat R, Ponikowski P, et al. State-of-the-art review: Mechanisms and clinical consequences of untreated central sleep apnea in heart failure. J Am Coll Cardiol 2015;65:72-84.
  2. Costanzo M, et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. The Lancet. 2016; 388: 974–82.
Am I a candidate
for remedē®?
CLOSE

For Patients

IMPORTANT SAFETY INFORMATION

The remedē® System is indicated for moderate to severe Central Sleep Apnea in adult patients.

Your doctor will need to evaluate your condition to determine if the remedē system is right for you. You will not be able to have an MRI or diathermy (special heat therapies) if you have the remedē system implanted. The remedē system may be used if you have another stimulation device such as a heart pacemaker or defibrillator; special testing will be needed to ensure the devices are not interacting.

As with any surgically implanted device, there are risks related to the surgical procedure itself which may include, but are not limited to, pain, swelling, and infection.

Once the therapy is turned on, some patients may experience discomfort from stimulation and/or from the presence of the device. The majority of these events are resolved either on their own or by adjusting the therapy settings. The remedē system may not work for everyone. There are additional risks associated with removing your system. If you and your doctor decide to remove the system, another surgery will be required.

Be sure to talk with your doctor so that you thoroughly understand all of the risks and benefits associated with the implantation of the remedē system. Rx only. For further information, please call +1-952-540-4470 or email info@respicardia.com.